Agil 100 EC

Primær information

  • Handelsnavn:
  • Agil 100 EC Emulsionskoncentrat
  • Lægemiddelform:
  • Emulsionskoncentrat
  • Sammensætning:
  • 100 g/l propaquizafop
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • Agil 100 EC Emulsionskoncentrat
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Markedsført
  • Autorisationsnummer:
  • Må ikke anvendes nærmere end 2 meter fra vandmiljøet (vandløb, søer m.v.) for at beskytte organismer, der lever i vand (SPe3).
  • Sidste ændring:
  • 22-07-2018
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.

29-6-2018

Pending EC decision:  Rapamune, sirolimus, Opinion date: 28-Jun-2018

Pending EC decision: Rapamune, sirolimus, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  Jinarc, tolvaptan, Opinion date: 28-Jun-2018

Pending EC decision: Jinarc, tolvaptan, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  Opdivo, nivolumab, Opinion date: 28-Jun-2018

Pending EC decision: Opdivo, nivolumab, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  Lenvima, lenvatinib, Opinion date: 28-Jun-2018

Pending EC decision: Lenvima, lenvatinib, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  Mepsevii, vestronidase alfa, Opinion date: 28-Jun-2018

Pending EC decision: Mepsevii, vestronidase alfa, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  Veyvondi, vonicog alfa, Opinion date: 28-Jun-2018

Pending EC decision: Veyvondi, vonicog alfa, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  Dexdor, dexmedetomidine, Opinion date: 28-Jun-2018

Pending EC decision: Dexdor, dexmedetomidine, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  Nerlynx, neratinib, Opinion date: 28-Jun-2018

Pending EC decision: Nerlynx, neratinib, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  Kymriah, tisagenlecleucel, Opinion date: 28-Jun-2018

Pending EC decision: Kymriah, tisagenlecleucel, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  Inovelon, rufinamide, Opinion date: 28-Jun-2018

Pending EC decision: Inovelon, rufinamide, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  RoActemra, tocilizumab, Opinion date: 28-Jun-2018

Pending EC decision: RoActemra, tocilizumab, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

29-6-2018

Pending EC decision:  Cablivi, caplacizumab, Opinion date: 28-Jun-2018

Pending EC decision: Cablivi, caplacizumab, Opinion date: 28-Jun-2018

Europe - EMA - European Medicines Agency

22-6-2018

Pending EC decision:  Longrange, eprinomectin, Opinion date: 21-Jun-2018

Pending EC decision: Longrange, eprinomectin, Opinion date: 21-Jun-2018

Europe - EMA - European Medicines Agency

22-6-2018

Metronidazole intravenous infusion 500 mg/100 mL bag

Metronidazole intravenous infusion 500 mg/100 mL bag

Shortage and althernative supply of Metronidazole intravenous infusion 500 mg/100 mL bag

Therapeutic Goods Administration - Australia

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

12-6-2018

Blokhuis: harde feiten gif in sigaretten zeer zorgelijk

Blokhuis: harde feiten gif in sigaretten zeer zorgelijk

Teer, nicotine en koolmonoxide gehalten in sigaretten die gemeten worden volgens de Canadian Intense (CI) methode zijn minimaal twee keer zo hoog als de gehalten gemeten met de wettelijke voorgeschreven ISO methode waarmee de EU en dus ook Nederland werkt. In sommige gevallen liggen de gehaltes zelfs tot meer dan 20 keer hoger. Dat blijkt uit onderzoek van het RIVM, dat 100 sigaretten onder de loep nam. Staatssecretaris Paul Blokhuis (VWS) heeft als opdrachtgever het onderzoek vandaag in ontvangst genome...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

1-6-2018

Pending EC decision:  Nityr, nitisinone, Opinion date: 31-May-2018

Pending EC decision: Nityr, nitisinone, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Aimovig, erenumab, Opinion date: 31-May-2018

Pending EC decision: Aimovig, erenumab, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Rxulti, brexpiprazole, Opinion date: 31-May-2018

Pending EC decision: Rxulti, brexpiprazole, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Myalepta, metreleptin, Opinion date: 31-May-2018

Pending EC decision: Myalepta, metreleptin, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Hyrimoz, adalimumab, Opinion date: 31-May-2018

Pending EC decision: Hyrimoz, adalimumab, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Hefiya, adalimumab, Opinion date: 31-May-2018

Pending EC decision: Hefiya, adalimumab, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Xeljanz, tofacitinib, Opinion date: 31-May-2018

Pending EC decision: Xeljanz, tofacitinib, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Halimatoz, adalimumab, Opinion date: 31-May-2018

Pending EC decision: Halimatoz, adalimumab, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Tegsedi, inotersen, Opinion date: 31-May-2018

Pending EC decision: Tegsedi, inotersen, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Trazimera, trastuzumab, Opinion date: 31-May-2018

Pending EC decision: Trazimera, trastuzumab, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Translarna, ataluren, Opinion date: 31-May-2018

Pending EC decision: Translarna, ataluren, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

1-6-2018

Pending EC decision:  Exondys, eteplirsen, Opinion date: 31-May-2018

Pending EC decision: Exondys, eteplirsen, Opinion date: 31-May-2018

Europe - EMA - European Medicines Agency

28-5-2018

Pending EC decision:  Pexion, imepitoin, Opinion date: 25-May-2018

Pending EC decision: Pexion, imepitoin, Opinion date: 25-May-2018

Europe - EMA - European Medicines Agency

3-5-2018

CVM eSubmitter Webinar 1 Agenda

CVM eSubmitter Webinar 1 Agenda

CVM will host the first of a three-part webinar series to provide information on the use of CVM’s electronic submission tool, eSubmitter, in the new animal drug application approval process. These webinars will support the use of eSubmitter as we move to 100% electronic submission.

FDA - U.S. Food and Drug Administration

18-5-2018

EU/3/14/1328 (Roche Registration GmbH)

EU/3/14/1328 (Roche Registration GmbH)

EU/3/14/1328 (Active substance: 4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid) - Transfer of orphan designation - Commission Decision (2018)3149 of Fri, 18 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/14/T/01

Europe -DG Health and Food Safety

27-4-2018

Pending EC decision:  Eladynos, abaloparatide, Opinion date: 22-Mar-2018

Pending EC decision: Eladynos, abaloparatide, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Perjeta, pertuzumab, Opinion date: 26-Apr-2018

Pending EC decision: Perjeta, pertuzumab, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Yervoy, ipilimumab, Opinion date: 26-Apr-2018

Pending EC decision: Yervoy, ipilimumab, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Prolia, denosumab, Opinion date: 26-Apr-2018

Pending EC decision: Prolia, denosumab, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Dexxience, betrixaban, Opinion date: 22-Mar-2018

Pending EC decision: Dexxience, betrixaban, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Alsitek, masitinib, Opinion date: 18-Apr-2018

Pending EC decision: Alsitek, masitinib, Opinion date: 18-Apr-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Dzuveo, sufentanil, Opinion date: 26-Apr-2018

Pending EC decision: Dzuveo, sufentanil, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Sprycel, dasatinib, Opinion date: 26-Apr-2018

Pending EC decision: Sprycel, dasatinib, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Cimzia, certolizumab pegol, Opinion date: 26-Apr-2018

Pending EC decision: Cimzia, certolizumab pegol, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Carmustine Obvius, carmustine, Opinion date: 26-Apr-2018

Pending EC decision: Carmustine Obvius, carmustine, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Xeljanz, tofacitinib, Opinion date: 26-Apr-2018

Pending EC decision: Xeljanz, tofacitinib, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency

27-4-2018

Pending EC decision:  Tagrisso, osimertinib, Opinion date: 26-Apr-2018

Pending EC decision: Tagrisso, osimertinib, Opinion date: 26-Apr-2018

Europe - EMA - European Medicines Agency

20-4-2018

Pending EC decision:  Credelio, lotilaner, Opinion date: 19-Apr-2018

Pending EC decision: Credelio, lotilaner, Opinion date: 19-Apr-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Cabometyx , cabozantinib, Opinion date: 22-Mar-2018

Pending EC decision: Cabometyx , cabozantinib, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Nerlynx, neratinib, Opinion date: 22-Feb-2018

Pending EC decision: Nerlynx, neratinib, Opinion date: 22-Feb-2018

Europe - EMA - European Medicines Agency

23-3-2018

Pending EC decision:  Repatha, evolocumab, Opinion date: 22-Mar-2018

Pending EC decision: Repatha, evolocumab, Opinion date: 22-Mar-2018

Europe - EMA - European Medicines Agency